Coordinated selling by multiple top executives, including the CEO, may signal lack of confidence in near-term prospects. Traders should monitor for absence of positive catalysts or potential downside risks ahead of next earnings or clinical updates.
VERA drugs
VERA drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 23 $42.06entry
- T+1 · 9mo ago +0.74%α +0.00% · $42.37
- T+5 · 9mo ago −3.90%α −4.52% · $40.42
- T+20 · 8mo ago −3.16%α +0.78% · $40.73
- T+60 · 6mo ago −18.33%α −26.58% · $34.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four C-suite executives at Vera Therapeutics, including CEO Fordyce Marshall, sold shares in a coordinated open-market transaction on February 23, 2026, totaling approximately $977,000 in value. All sales were conducted at the same price, indicating a planned divestment during a single trading day.
Key Financial Metrics
Key Facts
- CEO Fordyce Marshall sold 16,925 shares for $710,577.51 in open-market transaction.
- Three other C-suite officers (Chief Regulatory, Chief Operating, and Chief Commercial Officers) collectively sold 6,348 shares for $266,514.78.
- All transactions occurred on the same day at the same price ($41.9839), suggesting coordination.
- Total insider selling cluster value: $977,092.29 in open-market sales.
Financial Impact
$977,092 in open-market share sales by C-suite executives
Risk Factors
- Perception of insider pessimism could pressure share price.
- Lack of offsetting insider buying increases net negative sentiment.
- Possible upcoming negative developments in clinical programs or funding outlook.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (4 trades, 7d window) | cluster-VERA-1772067545581 |
Track record
25 reports on VERA
12 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers